Clinical Trial Update: A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers [Phase 1]

View source ↗

Summary

This Phase 1 open-label trial evaluated safety and immunogenicity of VXA-G1.1-NN, an oral multi-dose adenoviral-vector Norovirus vaccine, in healthy adult volun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Norovirus Infection

Drugs mentioned

• VXA-G1.1-NN (adenoviral-vector Norovirus vaccine)

Snippet

Sponsor: Vaxart | Conditions: Norovirus Infections | Phase 1 | Status: COMPLETED